Summary
50 / 100 · Bulios Score
What speaks for it
- It could repay all its net debt from 2.3 years of operating profit.
- It has been profitable 5 years in a row.
What to watch
- Earnings per share fell by 53% a year over the last 3 years.
- It cut its dividend by 59% last year.
- The share price is above the Bulios Fair Price.
- Operating profit covers the interest on its debt only 1.7 times.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks expensiveBulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 16.8 USD for 1 USD of yearly profit. Over the last five years it was 12.3 USD on average.
Valuation in detailIs it growing?
It is shrinkingRevenue (USD)
Diluted EPS (USD)
Revenue grew by 7.5% a year over 5 years. Over the last 3 years it fell by 6.8% a year. Earnings per share fell by 53% a year over the last 3 years.
Growth in detailDoes it make money?
ReasonablyWhere 100 USD of revenue goes
- Cost of sales 69 USD
- Research and development 0.8 USD
- Sales and administration 19 USD
- Taxes and other 8.8 USD
- Net profit 1.6 USD
Net profit, industry median (Chemicals - Specialty) 5.9 USD
Out of every 100 USD of revenue, 1.6 USD is left as net profit.
Profitability in detailIs it financially healthy?
Debt is a burdenRepaying all its debt would take 32.4 years of free cash flow. Its debt is larger than its cash.
Financial health in detailDoes it pay a dividend?
Small, safe- Yield
- 0.62%
- Paid out of profit
- 10%
You receive $0.17 per share a year. The company covers the payout with ease.
Dividends in detailWhat do analysts expect?
No coverageNo analyst covers this stock.
Analysts in detailWhat does it earn on?
By product
The company reports no revenue by product.
By region
The company reports no revenue by region.